Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Graft-Versus-Host Disease

Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation

Bone Marrow Transplantation volume 36, pages 1009–1015 (2005)Cite this article

Summary:

Donor lymphocyte infusions (DLI) have been the mainstay of treatment for chronic myeloid leukemia (CML) relapsing after allogeneic stem cell transplantation (allo-SCT). Imatinib mesylate (IM) is also effective in these patients. However, advanced phase relapse (APRel) responds poorly with either treatment. To test the possibility that combinations of DLI and IM might be more effective, 37 patients with CML relapsing after allo-SCT between August 1994 and May 2004 were studied. Ten had molecular relapse (MRel), 14 hematological relapse (HRel) and 13 APRel. Thirteen received DLI, 9 IM and 11 DLI+IM. Four patients received DLI+IM but not concurrently. Thirty (81%) patients responded (actuarial survival and current leukemia-free survival of 80.6±6.7% and 69.1±7.7%). Of 30 patients, 26 are in molecular remission (MR), median follow-up of 1226 days (range 249–3257) since relapse. Ten of 11 patients (including four with APRel) treated with DLI+IM achieved MR in 3 months and all are alive in MR. In contrast, only two of 22 treated with either modality (1/13 DLI and 1/9 IM) achieved MR at 3 months, 15 are alive, 11 in MR. Four patients receiving nonconcurrent DLI+IM are also alive in MR. In conclusion, DLI appears to synergize with IM to induce rapid and durable MR.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Goldman JM . Chronic myeloid leukemia-still a few questions. Exp Hematol 2004; 32: 2–10.

    Article  PubMed  Google Scholar 

  2. Kolb HJ, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462–2465.

    CAS  PubMed  Google Scholar 

  3. Porter DL, Roth MS, McGarigle C et al. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994; 330: 100–106.

    Article  CAS  PubMed  Google Scholar 

  4. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041–2050.

    CAS  PubMed  Google Scholar 

  5. Collins Jr RH, Shpilberg O, Drobyski WR et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433–444.

    Article  PubMed  Google Scholar 

  6. Michallet AS, Nicolini F, Furst S et al. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT). Bone Marrow Transplant 2005; 35: 601–608.

    Article  CAS  PubMed  Google Scholar 

  7. Alyea EP, Soiffer RJ, Canning C et al. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 1998; 91: 3671–3680.

    CAS  PubMed  Google Scholar 

  8. Roman J, Alvarez MA, Torres A . Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation. Haematologica 2000; 85: 1072–1082.

    CAS  PubMed  Google Scholar 

  9. Barrett AJ, Locatelli F, Treleaven JG et al. Second transplants for leukaemic relapse after bone marrow transplantation: high early mortality but favourable effect of chronic GVHD on continued remission. A report by the EBMT Leukaemia Working Party. Br J Haematol 1991; 79: 567–574.

    Article  CAS  PubMed  Google Scholar 

  10. Arcese W, Goldman JM, D’Arcangelo E et al. Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Chronic Leukemia Working Party. European Bone Marrow Transplantation Group. Blood 1993; 82: 3211–3219.

    CAS  PubMed  Google Scholar 

  11. Olavarria E, Ottmann OG, Deininger M et al. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 2003; 17: 1707–1712.

    Article  CAS  PubMed  Google Scholar 

  12. Kantarjian HM, O’Brien S, Cortes JE et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002; 100: 1590–1595.

    CAS  PubMed  Google Scholar 

  13. DeAngelo DJ, Hochberg EP, Alyea EP et al. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clin Cancer Res 2004; 10: 5065–5071.

    Article  CAS  PubMed  Google Scholar 

  14. Ullmann AJ, Hess G, Kolbe K et al. Current results on the use of imatinib mesylate in patients with relapsed Philadelphia chromosome positive leukemia after allogeneic or syngeneic hematopoietic stem cell transplantation. Keio J Med 2003; 52: 182–188.

    Article  PubMed  Google Scholar 

  15. Kim YJ, Kim DW, Lee S et al. Cytogenetic clonal evolution alone in CML relapse post-transplantation does not adversely affect response to imatinib mesylate treatment. Bone Marrow Transplant 2004; 33: 237–242.

    Article  CAS  PubMed  Google Scholar 

  16. Speck B, Bortin MM, Champlin R et al. Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia. Lancet 1984; 1: 665–668.

    Article  CAS  PubMed  Google Scholar 

  17. Craddock C, Szydlo RM, Klein JP et al. Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission. Blood 2000; 96: 86–90.

    CAS  PubMed  Google Scholar 

  18. Agarwal R, Doren S, Hicks B, Dunbar CE . Long-term culture of chronic myelogenous leukemia marrow cells on stem cell factor-deficient stroma favors benign progenitors. Blood 1995; 85: 1306–1312.

    CAS  PubMed  Google Scholar 

  19. Mensink E, van de LA, Schattenberg A et al. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR. Br J Haematol 1998; 102: 768–774.

    Article  CAS  PubMed  Google Scholar 

  20. Dazzi F, Szydlo RM, Cross NC et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2000; 96: 2712–2716.

    CAS  PubMed  Google Scholar 

  21. Lange T, Deininger M, Brand R et al. BCR-ABL transcripts are early predictors for hematological relapse in chronic myeloid leukemia after hematopoietic cell transplantation with reduced intensity conditioning. Leukemia 2004; 18: 1468–1475.

    Article  CAS  PubMed  Google Scholar 

  22. Radich JP, Gehly G, Gooley T et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 1995; 85: 2632–2638.

    CAS  PubMed  Google Scholar 

  23. O’Brien SG, Guilhot F, Larson RA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004.

    Article  PubMed  Google Scholar 

  24. Ullmann AJ, Beck J, Kolbe K et al. Clinical and laboratory evaluation of patients treated with STI-571 (Gleevec) after allogeneic and syngeneic stem cell transplantation with relapsed Philadelphia chromosome-positive leukemia [abstract]. Blood 2001; 98: 1685.

    Google Scholar 

  25. Dazzi F, Szydlo RM, Goldman JM . Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand. Exp Hematol 1999; 27: 1477–1486.

    Article  CAS  PubMed  Google Scholar 

  26. Rodriguez R, Snyder D, Nademanee A et al. Gleevec for relapsed CML after allogeneic transplant may overcome need for donor leucocyte infusions (DLI) or interferon (IFN) [abstract]. Blood 2001; 98: 1684.

    Google Scholar 

  27. Chambon-Pautas C, Cony-Makhoul P, Giraudier S et al. Glivec (STI571) treatment for chronic myelogenous leukemia (CML) in relapse after allogeneic stem cell transplantation (SCT): a report of the French experience (on behalf of the SFGM and FILMC) [abstract]. Blood 2001; 98: 587.

    Google Scholar 

  28. Ullmann AJ, Beck J, Meinhardt P et al. STI-571 in patients with relapsed Philadelphia chromosome-positive leukemia after allogeneic or syngeneic SCT [abstract]. Bone Marrow Transplant 2002; 27 (suppl. 1): P433.

    Google Scholar 

  29. Cwynarski K, Laylor R, Macchiarulo E et al. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 2004; 18: 1332–1339.

    Article  CAS  PubMed  Google Scholar 

  30. Seggewiss R, Lore K, Greiner E et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005; 105: 2473–2479.

    Article  CAS  PubMed  Google Scholar 

  31. Mackinnon S, Papadopoulos EB, Carabasi MH et al. Adoptive immunotherapy evaluating escalating doses of donor leucocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86: 1261–1268.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematology Branch, NHLBI, National Institutes of Health, Bethesda, MD, USA

    B N Savani, A Montero, R Childs, N Hensel & A J Barrett

  2. Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, USA

    R Kurlander

Authors
  1. B N Savani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Montero
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Kurlander
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R Childs
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N Hensel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A J Barrett
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A J Barrett.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Savani, B., Montero, A., Kurlander, R. et al. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant 36, 1009–1015 (2005). https://doi.org/10.1038/sj.bmt.1705167

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705167

Keywords

This article is cited by

Search

Advanced search

Quick links